Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. more
Time Frame | SLS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.22% | -3.39% | 0.2% |
1-Month Return | -31.65% | -1.92% | 2.72% |
3-Month Return | -30.02% | -10.54% | 7.31% |
6-Month Return | -29.46% | -4.47% | 10.44% |
1-Year Return | -21.28% | 4.06% | 27.53% |
3-Year Return | -86.2% | 0.94% | 30.88% |
5-Year Return | -76.98% | 36.67% | 89.21% |
10-Year Return | -100% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 1.90K | 7.60M | 1.00M | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":13.16,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | 200.00K | 100.00K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":50,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | 1.90K | 7.40M | 900.00K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.16,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | 100.00% | 97.37% | 90.00% | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.37,"profit":true},{"date":"2022-12-31","value":90,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 17.21M | (18.88M) | 32.69M | 42.85M | 37.87M | [{"date":"2019-12-31","value":40.16,"profit":true},{"date":"2020-12-31","value":-44.07,"profit":false},{"date":"2021-12-31","value":76.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":88.38,"profit":true}] |
Operating Income | (20.04M) | (16.98M) | (25.29M) | (41.95M) | (37.87M) | [{"date":"2019-12-31","value":-2004100000,"profit":false},{"date":"2020-12-31","value":-1698200000,"profit":false},{"date":"2021-12-31","value":-2529400000,"profit":false},{"date":"2022-12-31","value":-4195000000,"profit":false},{"date":"2023-12-31","value":-3786900000,"profit":false}] |
Total Non-Operating Income/Expense | 786.00K | 16.99M | 4.36M | 966.00K | 1.17M | [{"date":"2019-12-31","value":4.63,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":25.68,"profit":true},{"date":"2022-12-31","value":5.69,"profit":true},{"date":"2023-12-31","value":6.89,"profit":true}] |
Pre-Tax Income | (19.37M) | (16.77M) | (20.94M) | (41.30M) | (37.34M) | [{"date":"2019-12-31","value":-1937300000,"profit":false},{"date":"2020-12-31","value":-1677400000,"profit":false},{"date":"2021-12-31","value":-2093600000,"profit":false},{"date":"2022-12-31","value":-4130100000,"profit":false},{"date":"2023-12-31","value":-3734000000,"profit":false}] |
Income Taxes | (81.00K) | (17.00K) | (237.00K) | (649.00K) | (37.87M) | [{"date":"2019-12-31","value":-8100000,"profit":false},{"date":"2020-12-31","value":-1700000,"profit":false},{"date":"2021-12-31","value":-23700000,"profit":false},{"date":"2022-12-31","value":-64900000,"profit":false},{"date":"2023-12-31","value":-3786900000,"profit":false}] |
Income After Taxes | (19.29M) | (16.76M) | (20.70M) | (40.65M) | 529.00K | [{"date":"2019-12-31","value":-3646.88,"profit":false},{"date":"2020-12-31","value":-3167.67,"profit":false},{"date":"2021-12-31","value":-3912.85,"profit":false},{"date":"2022-12-31","value":-7684.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (19.29M) | (16.76M) | (20.70M) | (41.30M) | (38.33M) | [{"date":"2019-12-31","value":-1929200000,"profit":false},{"date":"2020-12-31","value":-1675700000,"profit":false},{"date":"2021-12-31","value":-2069900000,"profit":false},{"date":"2022-12-31","value":-4130100000,"profit":false},{"date":"2023-12-31","value":-3832500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (19.29M) | (16.76M) | (20.70M) | (40.65M) | (37.34M) | [{"date":"2019-12-31","value":-1929200000,"profit":false},{"date":"2020-12-31","value":-1675700000,"profit":false},{"date":"2021-12-31","value":-2069900000,"profit":false},{"date":"2022-12-31","value":-4065200000,"profit":false},{"date":"2023-12-31","value":-3734000000,"profit":false}] |
EPS (Diluted) | (21.72) | (2.13) | (1.33) | (2.23) | (1.36) | [{"date":"2019-12-31","value":-2172,"profit":false},{"date":"2020-12-31","value":-213,"profit":false},{"date":"2021-12-31","value":-133,"profit":false},{"date":"2022-12-31","value":-223,"profit":false},{"date":"2023-12-31","value":-136,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SLS | |
---|---|
Cash Ratio | 1.99 |
Current Ratio | 2.26 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SLS | |
---|---|
ROA (LTM) | -129.15% |
ROE (LTM) | -888.06% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SLS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.40 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.60 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SLS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 26.90 |
P/B | 4.07 |
Price/FCF | NM |
EV/R | 20.84 |
EV/Ebitda | NM |
Sellas Life Sciences Group Inc (SLS) share price today is $0.904
Yes, Indians can buy shares of Sellas Life Sciences Group Inc (SLS) on Vested. To buy Sellas Life Sciences Group Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Sellas Life Sciences Group Inc (SLS) via the Vested app. You can start investing in Sellas Life Sciences Group Inc (SLS) with a minimum investment of $1.
You can invest in shares of Sellas Life Sciences Group Inc (SLS) via Vested in three simple steps:
The 52-week high price of Sellas Life Sciences Group Inc (SLS) is $1.72. The 52-week low price of Sellas Life Sciences Group Inc (SLS) is $0.5.
The price-to-earnings (P/E) ratio of Sellas Life Sciences Group Inc (SLS) is
The price-to-book (P/B) ratio of Sellas Life Sciences Group Inc (SLS) is 4.07
The dividend yield of Sellas Life Sciences Group Inc (SLS) is 0.00%
The market capitalization of Sellas Life Sciences Group Inc (SLS) is $62.06M
The stock symbol (or ticker) of Sellas Life Sciences Group Inc is SLS